Bliss GVS Pharma reports strong financial performance in Q1 FY25

Bliss GVS Pharma, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ended June 2024. The company has shown positive performance in this quarter, with a steady score in the last three months.

One of the key highlights of the financial report is the growth in Profit Before Tax (PBT) by 56.89% Year on Year (YoY), reaching Rs 25.95 crore. This is a very positive trend for the company in the near term. Similarly, the Profit After Tax (PAT) has also shown a growth of 40.9% YoY, reaching Rs 20.70 crore. This indicates a strong financial performance for Bliss GVS Pharma.

Another positive aspect of the financial report is the company’s Operating Cash Flow, which has been the highest in the last three years at Rs 152.45 crore. This shows that the company has generated higher cash revenues from its business operations. Additionally, the company’s Cash and Cash Equivalents have also been the highest in the last six half yearly periods at Rs 215.62 crore, indicating an improvement in short term liquidity.

However, one area of concern for Bliss GVS Pharma is its Debtors Turnover Ratio, which has been the lowest at 1.90 times in the last five half yearly periods. This suggests that the company’s pace of settling its debtors has slowed down.

Overall, the financial results for the quarter ended June 2024 show a positive performance for Bliss GVS Pharma. MarketsMOJO has given a ‘Hold’ call for the company’s stock, indicating a neutral stance. Investors can keep an eye on the company’s future financial reports to track its progress.